Unlike hormone receptor-positive breast cancer (HR+ BC)—the most common subtype (5)—TNBC does not respond to endocrine or HER2-targeted therapies, and its treatment primarily relies on chemotherapy (6). This evidence concerns the gene ERBB2 and breast cancer.